OSHA Inspection: MARTONE PAINTING COMPANY

Issued

Feb 1, 2013

Abate by

Mar 19, 2013

Penalty

Initial $2,000 · Current $1,000 Reduced

General-duty citation text

29 CFR 1926.62(d)(2)(v)(E):     Until the employer performed an employee exposure assessment as required under 29 CFR 1926.62(d) and determined actual employee exposure, the employer did not provide to employees performing the tasks described in 29 CFR 1926.62(d)(2)(i), (d)(2)(ii), (d)(2)(iii), and (d)(2)(iv) with biological monitoring in accordance with 1926.62(j)(1)(i), to consist of blood sampling and analysis for lead and zinc protoporphyrin levels:    Worksite:  On or about 9/6/12 the employer did not ensure that employees involved with the manual scraping of paint assumed to contain lead received biological monitoring for their blood lead and zinc protoporphrin levels prior to starting the removal process.

Issued

Feb 1, 2013

Abate by

Feb 11, 2013

Penalty

Initial $0 · Current $0

General-duty citation text

29 CFR 1926.62(j)(2)(i)(B):     The employer did not make available biological monitoring in the form of blood sampling and analysis for lead and zinc protoporphyrin levels to each employee covered under 29 CFR 1926.62(j)(1)(i) or (ii) whose last blood sampling and analysis indicated a blood lead level at or above 40 micrograms per deciliter, at least every two months until two consecutive blood samples and analyses indicated a blood lead level below 40 micrograms per deciliter:    Worksite: On or about 10/16/12  the employer had not made available to employees with blood lead levels at or above 40 micrograms per deciliter as measured on 9/8/12 with follow up biological monitoring in the form of blood sampling and analysis for lead and zinc protoporphyrin levels within 2 months.

Issued

Feb 1, 2013

Abate by

Feb 11, 2013

Penalty

Initial $0 · Current $0

General-duty citation text

29 CFR 1926.62(j)(2)(ii):     The employer did not provide a second (follow-up) blood sampling test within two weeks after the employer received the results of the first blood sampling test when the first blood lead level test results indicated that the employee's blood lead level exceeded the numerical criterion for medical removal under 29 CFR 1926.62(k)(1)(i):    Worksite:  On or about (10/16/12) the employer had not made available to an employee with blood lead levels at or above 50 micrograms per deciliter as measured on 9/8/12 with follow up biological monitoring in the form of blood sampling and analysis for lead and zinc protoporphyrin levels within 2 weeks.

Issued

Feb 1, 2013

Abate by

Mar 19, 2013

Penalty

Initial $2,000 · Current $1,000 Reduced

General-duty citation text

29 CFR 1926.62(d)(3)(i):     The employer did not monitor employee exposures and did not base the initial determinations on the employee exposure monitoring results and any of the relevant considerations described in 29 CFR 1926.62(d)(3)(i)(A) through (C):    Worksite: On or about 9/6/12 the employer had not conducted employee exposure monitoring and had not based employee exposure on the relevant considerations described in 29 CFR 1926.62(d)(3)(i)(A) through ( C ) of the OSHA Standard.

Issued

Feb 1, 2013

Abate by

Jun 10, 2013

Penalty

Initial $2,800 · Current $1,400 Reduced

General-duty citation text

29 CFR 1926.62(l)(1)(iii):     The employer did not provide the training program required under 29 CFR 1926.62(l)(2) as initial training prior to the time of job assignment:    Worksite:    On or about 9/6/12, the employer had not provided all of the the initial required training program topics to four of the seven employees involved with lead paint removal.

Issued

Feb 1, 2013

Abate by

Jun 12, 2013

Penalty

Initial $0 · Current $0

General-duty citation text

29 CFR 1926.62(l)(2):     Employees were not trained in the requirements of 1926.62(l)(2)(i), (l)(2)(iv), and (l)(2)(viii):    Worksite: On or about 9/6/12, the employer had not provided the following training program topics annually to employees involved with lead paint removal: The content of the standard and it's appendices; the purpose and a description of the medical surveillance program, and the medical removal program including information concerning the adverse health effects associated with excessive exposure to lead; and the employees right of access to records under 29 CFR 1910.20.

Issued

Feb 1, 2013

Abate by

Mar 19, 2013

Penalty

Initial $0 · Current $0

General-duty citation text

29 CFR 1904.32(b)(3):     The person who certified the annual summary was not a company executive as defined in 29 CFR 1904.32(b)(4):    Employer's Office:  On or about 10/26/12  the employer did not ensure that the 2012 OSHA Form 300 annual summary was certified by a company executive.